We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Article |

Investigational New Drug (US) 'Orphan' Trials Now Use Thalidomide From Two Sources

Teri Randall
JAMA. 1990;263(11):1474. doi:10.1001/jama.1990.03440110028005.
Text Size: A A A
Published online


FOOD AND DRUG Administration (FDA) officials classify thalidomide as an orphan drug, one of 133 such pharmaceuticals currently being studied in the treatment of 96 relatively rare diseases (JAMA. 1990;263:793).

Two such studies of thalidomide are under way. In lepromatous leprosy, it has been the drug of choice since 1966 in treating erythema nodosum leprosum and now is in phase III (extensive clinical trials in humans) developmental status. In graft-versus-host disease, the most common cause of death following bone marrow transplantation, it has been in clinical trials since 1987 and is in phase II (effectiveness testing in humans) developmental status. (Please see accompanying article.)

In the United States, thalidomide is obtained under investigational new drug status from two sources. The National Hansen's Disease Center, Carville, La, which is conducting the leprosy study, obtains reagent-grade thalidomide from Andrulis Research Corporation, Bethesda, Md.

Andrulis manufactures the drug under contract with the US


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.